{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:16:19Z","timestamp":1777954579661,"version":"3.51.4"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:sup>68<\/jats:sup>\n                    Ga-CXCR4 PET\/CT was performed in a patient with acute myeloid leukemia (AML) and granulocytic sarcoma in the left cervical region, who had previously undergone\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT. Compared with\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT,\n                    <jats:sup>68<\/jats:sup>\n                    Ga-CXCR4 PET\/CT revealed a greater number of malignant lymph nodes with more intense uptake in both supradiaphragmatic and infradiaphragmatic regions. Furthermore, markedly increased radiotracer uptake was observed in the bone marrow and spleen compared with FDG. This case underscores the superior sensitivity of\n                    <jats:sup>68<\/jats:sup>\n                    Ga-CXCR4 PET\/CT in detecting AML infiltration and supports further investigation of CXCR4-targeted imaging and therapeutic approaches in high-risk AML.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006052","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T19:00:12Z","timestamp":1752260412000},"page":"e395-e397","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["68Ga-CXCR4-targeted PET\/CT Outperforms 18F-FDG PET\/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma"],"prefix":"10.1097","volume":"51","author":[{"given":"\u00d6zlem","family":"Beyler","sequence":"first","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halil","family":"K\u00f6mek","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gazi Ya\u015fargil Training and Research Hospital, University of Health Sciences, Diyarbakir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8555-0460","authenticated-orcid":false,"given":"Yunus","family":"G\u00fczel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gazi Ya\u015fargil Training and Research Hospital, University of Health Sciences, Diyarbakir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cengiz","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Hematology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan","family":"Can","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gazi Ya\u015fargil Training and Research Hospital, University of Health Sciences, Diyarbakir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.blre.2017.01.003","article-title":"Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia","volume":"31","author":"Percival","year":"2017","journal-title":"Blood Rev"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ejh.12085","article-title":"Extramedullary disease in patients with acute myeloid leukemia assessed by 18F-FDG PET","volume":"90","author":"Cribe","year":"2013","journal-title":"Eur J Haematol"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3324\/haematol.2019.223032","article-title":"The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET\/CT: final results from the prospective PETAML trial","volume":"105","author":"St\u00f6lzel","year":"2020","journal-title":"Haematologica"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3324\/haematol.2016.142976","article-title":"Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia","volume":"8","author":"Herhaus","year":"2016","journal-title":"Haematologica"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","article-title":"Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches","volume":"25","author":"Sugiyama","year":"2006","journal-title":"Immunity"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","article-title":"CXCL12 (SDF-1)\/CXCR4 pathway in cancer","volume":"16","author":"Teicher","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.18632\/oncotarget.3217","article-title":"CXCR4 over-expression and survival in cancer: a system review and meta-analysis","volume":"7","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1097\/RLU.0000000000005731","article-title":"68 Ga-Pentixafor PET\/CT-based response evaluation and its prognostic value in multiple myeloma: comparison with IMWG and 18 F-FDG-based response","volume":"50","author":"Kaur","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R9-20260504","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/RLU.0000000000005770","article-title":"Clinical application of 68Ga-Pentixafor PET\/CT for the detection of thymoma: a pilot study","volume":"50","author":"Wang","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2006-05-024844","article-title":"CXCR4 is a prognostic marker in acute myelogenous leukemia","volume":"109","author":"Spoo","year":"2007","journal-title":"Blood"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:01:11Z","timestamp":1777921271000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006052"}},"subtitle":["Theranostic Insights"],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006052","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"2025-05-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}